Additionally, pharmacological PPARγ activation improves the metabolic milieu and steatosis; it also suppresses NF-κB and c-Jun N-terminal kinase (JNK) activation, neutrophil, and F4/80 macrophage recruitment in diabetes-related NASH [51]. Here, NFKB1 is linked to metabolic dysfunction-associated steatohepatitis.